Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Short Interest Update

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) was the recipient of a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 200 shares, a growth of 100.0% from the May 31st total of 100 shares. Based on an average daily trading volume, of 404,500 shares, the short-interest ratio is currently 0.0 days.

Shionogi & Co., Ltd. Stock Up 0.3 %

OTCMKTS:SGIOY traded up $0.03 during mid-day trading on Friday, reaching $9.71. The stock had a trading volume of 634,669 shares, compared to its average volume of 260,377. The business’s 50 day moving average is $10.90 and its 200 day moving average is $11.78. Shionogi & Co., Ltd. has a fifty-two week low of $9.35 and a fifty-two week high of $13.67. The stock has a market cap of $11.52 billion, a P/E ratio of 10.01, a PEG ratio of 2.71 and a beta of 0.25. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.86 and a quick ratio of 5.37.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last announced its quarterly earnings results on Monday, May 13th. The company reported $0.21 EPS for the quarter. Shionogi & Co., Ltd. had a return on equity of 13.20% and a net margin of 37.29%. The company had revenue of $662.08 million for the quarter. As a group, sell-side analysts predict that Shionogi & Co., Ltd. will post 0.87 earnings per share for the current year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.